Navigation Links
Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference
Date:6/3/2008

IRVINE, Calif., June 3 /PRNewswire-FirstCall/ -- Masimo Corporation (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through-Motion-and-Low-Perfusion pulse oximetry, today announced that it is scheduled to present at the Goldman Sachs 29th Annual Global Healthcare Conference at The Ritz Carlton, Laguna Nigel, in Dana Point, CA, on Wednesday, June 11, 2008, at 2:40 p.m. PT. Joe E. Kiani, Chairman and CEO, will be presenting.

A live audiocast of the presentation will be available on the Masimo website at http://www.masimo.com. A replay of the audiocast will be available following the live presentation.

About Masimo

Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.


'/>"/>
SOURCE Masimo Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference
2. Masimo Reports First Quarter 2008 Financial Results
3. Atom Medical Adopts Masimo Rainbow SET Technology
4. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
5. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
6. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
7. Masimo Announces Continuous Noninvasive Total Hemoglobin
8. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
9. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
10. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
11. Masimo to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):